Wollina et al., 2001 - Google Patents
Serum matrix metalloproteinase-2 in patients with malignant melanomaWollina et al., 2001
- Document ID
- 14178791147877013020
- Author
- Wollina U
- Hipler U
- Knöll B
- Graefe T
- Kaatz M
- Kirsch K
- Publication year
- Publication venue
- Journal of cancer research and clinical oncology
External Links
Snippet
Purpose: Matrix metalloproteinases (MMPs) are a family of structurally related zinc- dependent endopeptidases that are able to degrade extracellular matrix components. MMPs play a role in tumor invasion and tumor metastasis. MMP-2 (also known as gelatinase A) is …
- 206010025650 Malignant melanoma 0 title abstract description 46
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nikkola et al. | High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma | |
Catalona et al. | Measurement of prostate-specific antigen in serum as a screening test for prostate cancer | |
Platts et al. | Death from phaeochromocytoma: lessons from a post-mortem survey | |
RU2580626C2 (en) | Use of vap-1 inhibitors for fibrotic sickness treatment | |
Väisänen et al. | Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma | |
Wang et al. | Post-treatment surveillance of thyroid cancer | |
Schlagenhauff et al. | Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? | |
CA2330628A1 (en) | Method for diagnosing a vascular condition | |
JP2013083665A (en) | Use of melanoma inhibitory activity (mia) protein as early indicator for therapeutic response in melanoma | |
Larrinaga et al. | Prolyl endopeptidase activity is correlated with colorectal cancer prognosis | |
Protheroe et al. | Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer | |
Glimelius et al. | Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements | |
Wollina et al. | Serum matrix metalloproteinase-2 in patients with malignant melanoma | |
Karvonen et al. | An animal model of pulmonary radiation fibrosis with biochemical, physiologic, immunologic, and morphologic observations | |
Khongkhunthian et al. | Elevated levels of a disintegrin and metalloproteinase 8 in gingival crevicular fluid of patients with periodontal diseases | |
Jassem et al. | Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance | |
RU2219553C2 (en) | Method for determining autohemochemotherapy effectiveness in treating the cases of carcinoma affecting rectosigmoid portion of the rectum and sigmoid colon and autohemochemotherapy combined with ultrahigh frequency hyperthermia in treating the cases of rectal carcinoma | |
Sciarra et al. | Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma | |
Faraj et al. | Plasma L-dopa in the diagnosis of malignant melanoma. | |
RU2635535C1 (en) | Method for prediction of relapse development in patients with oral mucosa cancer | |
US6352834B1 (en) | Prostate cancer assays and related methods | |
EP1181939B1 (en) | Method for evaluating in vivo matrix metalloproteinase inhibitory activity | |
RU2548783C1 (en) | Method for preoperative determination of extent of surgery for high-differentiated thyroid carcinoma | |
RU2605838C1 (en) | Method for prediction of risk of biochemical recurrent in prostate cancer patients after radiation and hormone therapy | |
Moseley et al. | Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors |